Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Calciphylaxis: Beyond CKD-MBD.

María Fernández1, Enrique Morales1, Eduardo Gutierrez1

  • 1Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, España.

Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia
|April 10, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FINE-ONE, more to come: moving beyond ACEis and ARBs in type 1 diabetes with kidney disease?

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Emerging Cardiorenal Protective Therapies in Lupus Nephritis.

Drugs·2026
Same author

Short versus long corticosteroid therapy for immune checkpoint inhibitors-induced acute tubulointerstitial nephritis.

Clinical kidney journal·2026
Same author

Chronic kidney disease progression in glomerular diseases: is hematuria a key risk factor?

Pediatric nephrology (Berlin, Germany)·2026
Same author

Albuminuria in Lupus Nephritis: the hidden threat to cardiovascular health.

Rheumatology advances in practice·2026
Same author

Hematuria as a biomarker guiding treatment decisions in IgA nephropathy? Yes.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026

Calcific uraemic arteriolopathy (CUA) is a rare vascular disorder with high mortality, particularly in kidney transplant patients. Steroid use and chronic renal failure are key risk factors, necessitating further research into standardized treatments.

Area of Science:

  • Nephrology
  • Vascular Medicine
  • Dermatology

Background:

  • Calcific uraemic arteriolopathy (CUA), or calciphylaxis, is a rare, severe vascular disease predominantly affecting patients with chronic kidney disease.
  • Understanding CUA's risk factors and clinical outcomes is crucial due to its high mortality rate.

Purpose of the Study:

  • To investigate the risk factors associated with the development of CUA.
  • To analyze the clinical course and treatment outcomes of patients diagnosed with CUA.

Main Methods:

  • A retrospective analysis of 28 patients diagnosed with CUA between December 1999 and December 2015.
  • Evaluation of patient demographics, renal function status, treatment modalities, and survival rates.

Main Results:

Keywords:
Anticoagulantes oralesCalcifilaxisCalciphylaxisChronic renal failureFormas no renalesInsuficiencia renal crónicaMortalidadMortalityNon-renal formsOral anticoagulants

Related Experiment Videos

  • Steroid use was a significant risk factor in renal transplant patients (100%).
  • Skin lesions resolved in 60.7% of patients, particularly with multitargeted therapy.
  • 12-month survival rates varied: 29% for transplant, 57% for hemodialysis, and 100% for normal renal function patients.
  • Chronic renal failure and hypoalbuminemia were identified as major mortality risk factors.

Conclusions:

  • CUA, despite its low incidence, carries a high mortality rate, demanding increased attention in kidney transplant recipients and non-renal forms.
  • Oral anticoagulants and steroids are implicated as primary risk factors.
  • Establishing a patient registry and defining standard therapies are essential for managing this challenging condition.